The javascript used on this site for creative design effects is not supported by your browser. Please note that this will not affect access to the content on this web site.
Skip Navigation
H H S Department of Health and Human Services
Health Resources and Services Administration
HIV/AIDS Programs

A-Z Index  |  Questions? 

  • Print this
  • Email this

Part B: AIDS Drug Assistance Program

Part B of the Ryan White HIV/AIDS Treatment Extension Act of 2009 (Public Law 111-87) provides grants to States and U.S. Territories to improve the quality, availability, and organization of HIV/AIDS health care and support services. Part B grants include a base grant; the AIDS Drug Assistance Program (ADAP) award; ADAP Supplemental Drug Treatment Program funds; and supplemental grants to States with "emerging communities," defined as jurisdictions reporting between 500 and 999 cumulative AIDS cases over the most recent 5 years.


All 50 States, the District of Columbia, Puerto Rico, Guam, the U.S. Virgin Islands, and the five U.S. Pacific Territories or Associated Jurisdictions are eligible for funding. Emerging Communities are defined as those reporting between 500 and 999 cumulative reported AIDS cases over the most recent 5 years.


Funding Considerations

  • Congress designates, or "earmarks," a portion of the Part B appropriation for ADAP. This distinction is important because other Part B spending decisions are made locally. Five percent of the total earmark, however, is reserved for supplemental grants to States and Territories that have demonstrated severe need that prevents them from providing medications consistent with Public Health Service guidelines. Before the 2006 reauthorization, estimated living cases of AIDS was used in determining the formula, and three percent was reserved for supplemental grants.
  • A formula based on the number of reported living HIV/AIDS cases in the most recent calendar year is used to award ADAP funds to States and Territories.



ADAP provides medications for the treatment of HIV disease. Program funds may also be used to purchase health insurance for eligible clients and for services that enhance access to, adherence to, and monitoring of drug treatments.



Each grantee establishes its own ADAP eligibility criteria. All grantees, however, are required to implement an ADAP recertification process every 6 months to ensure that only eligible clients are served. All grantees require that program participants document their HIV status, and nine programs require a CD4 count of 500 or less. Fifteen States have established income eligibility at 200 percent or less of the Federal Poverty Level (FPL).

The ADAP in each State and Territory is unique in that it decides which medications will be included in its formulary and how those medications will be distributed. However, current legislation requires that each grantee must cover all classes of approved HIV antiretrovirals on their ADAP formulary.

  • Many States and Territories provide medications through a pharmacy reimbursement model. Patients show enrollment cards at participating pharmacies to receive their medications, and the pharmacy invoices the ADAP for payment.
  • Some ADAPs use pharmacies located within public health clinics to distribute drugs.
  • A few ADAPs purchase drugs and mail them to clients directly.



Grants are awarded to all 50 States, the District of Columbia, Puerto Rico, Guam, the U.S. Virgin Islands, and a few Pacific jurisdictions.


Increasing Demand

Pressure on ADAP resources has increased substantially:

  • Highly active antiretroviral therapy (HAART) is the standard of care for a majority of people living with HIV disease. Its cost may be $12,000 or more per year. In addition, people living with HIV/AIDS face costs of treating opportunistic infections, managing side effects, and addressing other treatment issues.
  • AIDS mortality has decreased dramatically in the United States since 1995, and an estimated 56,000 new infections occur annually. Therefore, the total number of people living with HIV disease continues to climb.
  • The epidemic is growing rapidly among minorities, who have historically experienced higher risk for poverty, lack of health insurance, comorbidity, and disenfranchisement from the health care system. The result is a growing number of people living with HIV disease who require public support.
Part B - ADAP Resources

A Living History: Get the Back Story image.

Part B grew into the largest component of the Ryan White HIVAIDS Program primarily as a result of increases in funds to support access to drug therapies.

Quick Facts

As a result of the dramatic increase in the cost of pharmaceutical treatment and the growing number of people living with HIV/AIDS, the ADAP earmark is now the largest portion of Part B spending. The earmark has grown from $52 million in 1996 to $835 million appropriated for FY 2010. Total ADAP spending is even higher, however, because State ADAPs also receive money from their respective States, from other Ryan White HIV/AIDS Program components, and through cost-saving strategies.

Approximately 175,194 people received medications through ADAP in calendar year 2008, a 6.9 percent increase over the163,925 people served the previous year. None had adequate health insurance or the financial resources necessary to cover the cost of medications.

Many clients are enrolled in ADAP only temporarily while they await acceptance into other insurance programs, such as Medicaid. On average, 73,000 clients are served each month.

In FY 2008, 83 percent of ADAP clients have annual household incomes below 200 percent of FPL.

Of the 2,157 providers submitting data to HAB for 2008: 1,213 received Part A funds; 1,160 received Part B funds; 444 received Part C funds; and 263 received Part D funds.

Part B - ADAP Publications

Technical Assistance TARGET Center Library Exit Disclaimer

Part B: States and U.S. Territories Program Fact Sheet (PDF - 221 KB)